FDAnews
www.fdanews.com/articles/81754-dynogen-initiates-trial-of-ddp225-for-ibs-d

DYNOGEN INITIATES TRIAL OF DDP225 FOR IBS-D

October 18, 2005

Dynogen Pharmaceuticals has initiated a Phase II proof-of-concept trial of DDP225 for diarrhea-predominant irritable bowel syndrome (IBS-d), and the first patients have been dosed. DDP225 is an orally active compound that targets two key pathways that control the gastrointestinal (GI) system, thus giving it the potential to address multiple symptoms associated with IBS-d.

This DDP225 Phase II trial is a randomized, double-blind, placebo-controlled study that is enrolling patients with IBS-d at multiple centers in Canada and is assessing safety and pharmacodynamic efficacy as well as symptom-based endpoints. In September, Dynogen began dosing patients in a Phase II study of DDP733 for the treatment of patients with constipation-predominant IBS (IBS-c), the other common form of IBS.